Difference between revisions of "Necitumumab (Portrazza)"
m (Text replacement - "[[Media:" to "[[File:") |
m (Text replacement - "[[File:" to "[[:File:") |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Recombinant human IgG1 EGFR monoclonal antibody. Necitumumab binds to the human epidermal growth factor receptor (EGFR) prevents it from binding to its ligands. This interferes with EGFR's effects on growth of malignant cells, angiogenesis, and inhibition of apoptosis. In vitro, necitumumab has been observed to cause antibody-dependent cellular cytotoxicity (ADCC) in cells which express EGFR, induce the internalization of EGFR, and lead to its degradation.<ref name=insert>[http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf Necitumumab (Portrazza) package insert]</ref><ref>[[File:Necitumumab.pdf|Necitumumab (Portrazza) package insert (locally hosted backup)]]</ref><ref>[http://portrazza.com/ Portrazza manufacturer's website]</ref> | + | Class/mechanism: Recombinant human IgG1 EGFR monoclonal antibody. Necitumumab binds to the human epidermal growth factor receptor (EGFR) prevents it from binding to its ligands. This interferes with EGFR's effects on growth of malignant cells, angiogenesis, and inhibition of apoptosis. In vitro, necitumumab has been observed to cause antibody-dependent cellular cytotoxicity (ADCC) in cells which express EGFR, induce the internalization of EGFR, and lead to its degradation.<ref name=insert>[http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf Necitumumab (Portrazza) package insert]</ref><ref>[[:File:Necitumumab.pdf|Necitumumab (Portrazza) package insert (locally hosted backup)]]</ref><ref>[http://portrazza.com/ Portrazza manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
Revision as of 04:14, 20 September 2021
General information
Class/mechanism: Recombinant human IgG1 EGFR monoclonal antibody. Necitumumab binds to the human epidermal growth factor receptor (EGFR) prevents it from binding to its ligands. This interferes with EGFR's effects on growth of malignant cells, angiogenesis, and inhibition of apoptosis. In vitro, necitumumab has been observed to cause antibody-dependent cellular cytotoxicity (ADCC) in cells which express EGFR, induce the internalization of EGFR, and lead to its degradation.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brief patient counseling information can be found in the Necitumumab (Portrazza) package insert[1]
History of changes in FDA indication
- 11/24/2015: FDA approved to be used in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. (Based on SQUIRE)
Also known as
- Code name: IMC-11F8
- Brand name: Portrazza